Novartis receives EU approval for biosimilar Zessly

ZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological di…
Read the full story: Reuters: Health News